Stock Market Reviews

Read and share opinions on SVRA (Savara Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum
  Nov 14, 2025
• Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 12, 2025
• Savara Announces Participation in Upcoming Investor Healthcare Conferences
  Nov 3, 2025
• Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
  Oct 31, 2025
• What Does Wall Street Think About Savara Inc. (SVRA)?
  Oct 31, 2025
• Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
  Oct 30, 2025
• Savara Announces Proposed Public Offering
  Oct 29, 2025
• Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  Oct 29, 2025
• Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections
  Oct 29, 2025
• Savara Announces Chief Medical Officer (CMO) Transition
  Oct 17, 2025
• Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
  Oct 2, 2025
• Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
  Sep 29, 2025
• Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity
  Sep 20, 2025
• Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis
  Sep 2, 2025
• Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough
  Aug 23, 2025
• New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  Aug 20, 2025